Longevity startups face regulatory roadblock as first cellular rejuvenation therapy enters human trials
The first cellular rejuvenation therapy has reached human testing. Life Biosciences dosed its first patient with ER-100, using partial epigenetic reprogramming, after the FDA cleared the study. The catch: regulators recognize no aging indication, so each trial must target a speci
The science of reversing biological age just crossed a real threshold. Life Biosciences has dosed the first patient in a human trial of ER-100, the first cellular rejuvenation therapy built on partial epigenetic reprogramming to reach the clinic, after the FDA cleared its investigational application earlier this year. A separate startup, NewLimit, raised $435 million to fund its own first trial, which will begin in the liver. Yet the entire field runs into the same prosaic wall. The FDA does not recognize aging itself as a condition to treat, so no company can simply run a study to make people younger. Each therapy has to be aimed at a specific, recognized disease and prove it works there, which keeps any broad approval years away and forces longevity research to advance one narrow indication at a time. The money and the science are moving fast, but the regulatory path still decides how quickly any of this reaches ordinary patients.